Postpartum low-dose aspirin to augment vascular recovery following a hypertensive disorder of pregnancy

Active Project Grant Awarded Last action

Award ID
K23HL168356
Recipient
Awarding agency
Obligated
$1,190,032

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 81% complete
Place of performance
Rhode Island, USA

Award details come from USAspending.gov.

Description

Abstract
Cardiovascular disease (CVD) is the leading cause of death in women worldwide and despite declines in all other age groups, mortality rates attributed to CVD are increasing in women of childbearing age. Preeclampsia is a well-established risk factor for CVD across diverse patient populations, however, there are currently no evidence-based interventions targeting this at-risk patient population. While blood pressure control is the cornerstone of postpartum management, emerging evidence suggests that management of hypertension alone does not fully mitigate CVD risk after preeclampsia. The overall goal of this line of research is to begin to develop and test novel pharmacologic interventions for postpartum management following preeclampsia, representing a paradigm shift focused on endothelial recovery postpartum in addition to blood pressure control. In this application, the objective is to conduct a single-site pilot trial to assess the feasibility and effect of low- dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: to pilot test the feasibility of conducting a randomized controlled trial of postpartum low-dose aspirin VS. Placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. The research proposed in this application is innovative in its novel adaptation of an evidence-based strategy to improve vascular function and postpartum blood pressure in an understudied population with significant morbidity during a critical time period. This proposal is significant as IT will provide an opportunity to assess the feasibility and explore the effect of low-dose aspirin on vascular function in addition to blood pressure. Effective interventions to improve postpartum hypertension care and reduce long-term cardiovascular risk have broad implications for improving maternal morbidity and reducing disparities in care. Our findings will provide a valuable framework to inform a subsequent large-scale randomized trial of low-dose aspirin in the postpartum period following preeclampsia. Successful completion of this line of research would represent a transformation in postpartum management of women with hypertensive disorders of pregnancy and have a direct impact to improve hypertension and cardiovascular-related maternal morbidity and mortality.

Transactions

Action Obligated Date
Amendment $170,543
Amendment $172,223
Amendment $172,223
Amendment $172,223
Amendment -$43,257
Amendment $43,257
Amendment -$43,257
Amendment $43,257
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $167,722
Amendment $167,722
Amendment $0
Amendment $0
Original award $167,376
Show all 19

Subawards

Subrecipient Amount Awarded
Magee-Womens Research Institute And Foundation Postpartum low-dose aspirin to augment vascular recovery following a hypertensive disorder of pregnancy $14,808
Magee-Womens Research Institute And Foundation $51,441
University Of Pittsburgh - Of The Commonwealth System Of Higher Education Scope of Work Dr. Hauspurg will have primary responsibility for recruiting patients with preeclampsia during the delivery hospitalization. These subjects will… $135,756

Quick answers

Who received award K23HL168356?

K23HL168356 was awarded to Women & Infants Hospital Of Rhode Island by National Heart Lung and Blood Institute (National Institutes of Health) on August 7, 2023.

How much is award K23HL168356 worth?

$1,190,032 has been obligated on K23HL168356.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award